Critical Path Opportunities List Previewed By FDA
FDA’s Critical Path opportunities list will emphasize development in disease areas with “urgent needs” and “at risk” patient populations, CDER Director Galson says.
FDA’s Critical Path opportunities list will emphasize development in disease areas with “urgent needs” and “at risk” patient populations, CDER Director Galson says.